logo
Sign in or Register

Already a member?

Sign in

Or sign in with your account on:

Not a member yet?

Register
    
Stock in health insurers is broadly down on Thursday morning. Every major health insurer saw shares down in early trading, with a disappointing earnings report from industry-leader UnitedHealth Group Inc. (UNH)  that appeared to be dragging down the entire sector. UnitedHealth Beats Earnings Expectations, Undershoots UnitedHealth reported earnings of $1.1…
Read more...
Even in a year where the S&P 500 gained over 30 percent, one of the hottest segments of the entire economy last year was the biotech industry, with the iShares NASDAQ Biotechnology Index ETF (IBB) gaining almost 70 percent in 2013. However, the first half of 2014 has seen a…
Read more...
Keith Markey, veteran analyst and science director of Griffin Securities, tells us the 2014 pipeline calendar is positively glowing with important milestones that could ignite portfolios. In this interview with The Life Sciences Report, Markey talks about four powerful biotech names with exciting early- to late-stage development projects and one…
Read more...
Battleground stock Arena Pharmaceuticals (ARNA) appears to have been slightly shaken when CNBC’s Jim Cramer advised viewers to sell the stock yesterday. The heavily traded stock has been declining off of a peak reached in mid-January off of bullish expectations for its obesity drug Belviq (lorcaserin). However, since coming off…
Read more...
Cel-Sci Corporation (CVM) saw its stock plunge after pricing a public offering of over 7 million shares of stock. Pricing the units at $1.40 apiece for gross proceeds of $10 million. Each unit includes a share of common stock and a $0.25 warrant, exercisable immediately with an expiration date of…
Read more...
Small-cap biotech stock Lexicon Pharmaceuticals (LXRX) leapt as much as 17 percent in early trading on news that its lead therapy LX4211 showed positive top-line results in treating type 1 diabetes. However, early gains were followed by a rapid decline that ultimately saw the stock trading down over 2 percent.…
Read more...
Shares in Mast Therapeutics (MSTX) jumped on Monday following the presentation of data showing that its lead therapy MST-188 reduced the erythrocyte sedimentation rate (ESR) by 50 percent for blood collected from individuals with sickle cell anemia at the 8th Annual Sickle Cell Disease Research & Educational Symposium in Miami.…
Read more...
The race to produce the first effective Hepatitis C drug, and capture the massive profits that come with it, appears to have been won by Gilead Sciences (GILD) . At least, that is, for now. However, the price of Gilead's drug, Sovaldi, has raised serious questions about just what the…
Read more...
After soaring more than 56% last year, the NASDAQ Biotechnology Index is down almost 15% in March. In this interview with The Life Sciences Report, Jason Kolbert of the Maxim Group points to increased approval rates and a better economic and regulatory environment as the fundamentals behind a revaluation that…
Read more...
Shares in small-cap biopharmaceutical company Cytokinetics (CYTK) were on the move on Wednesday, though that should hardly be a surprise for a stock as volatile as Cytokinetics. Shares opened up $0.07 at $8.95 apiece with a big spike in volume at the open. And, while the volume quickly cooled off,…
Read more...
Shares in small-cap 3D-bioprinting company Organovo (ONVO) took a small hit on Tuesday following the release of “part II” of an attack on the company produced by the mysterious Simeon Research, declining just over 2.25 percent. Simeon, a company whose website features no contact information aside from an email and…
Read more...
In early March, shares of Gilead ($GILD) notched a five-year-high of $84.88 per share thanks to the company’s Hepatitis C super drug Sovaldi. Costing $1,000 for a single tablet, Sovaldi cures the most common type of Hepatitis C in 12 weeks and is proven effective for some hard-to-treat patients. Sovaldi…
Read more...
Page 1 of 36

About us

Equities.com is the most advanced interactive online social ecosystem for the financial industry, serving as a resource center and next-generation communication platform that connects self-directed investors with public issuers, market experts, and professional service providers and vendors. Registered members can leverage our exclusive proprietary research tools such as the Small-Cap Stars, which outperformed 90% of all small-cap mutual funds, and robust do-it-yourself E.V.A. research reports. The Equities.com Issuer Dashboard is the ideal tool to communicate and manage investor awareness campaigns to the investment community, as well as to access valuable resources to help your company grow.

Market Data powered by QuoteMedia.
Copyright © QuoteMedia. Data delayed 15 minutes unless otherwise indicated. Terms of Use.